entertainment -WSS

entertainment

author：comprehensive 2025-10-01 15:30:33 - browse：84287

STAT@ASCO 2024 — Chris Boshoff, far right, speaking at a panel with, from left, Matthew Herper of STAT, Ken Keller, Levi Garraway, and Susan Galbraith. Megan Bearder Photography

CHICAGO — The ways clinicians can treat cancers effectively are expanding, partly because technologies today are making old ideas possible, said a panel of oncology industry leaders at STAT@ASCO, STAT’s event here at the annual American Society of Clinical Oncology meeting.

“We’re seeing this expansion in modalities. We have more types of modalities that have arrived or arriving that allow us to exploit targets we’ve known about more than ever before. It’s very exciting,” said Levi Garraway, the chief medical officer of Genentech, at the event. “Things we’ve known about for a long time can be drugged for the first time or in a new, different way.”

That’s led to a surge of new medicines ranging from small molecules to cell therapies, with the potential uses of these treatments expanding into earlier lines of therapy and more cancer types each year. One example the panel singled out is the drug Enhertu, which recently received a tumor-agnostic approval from the Food and Drug Administration.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Dark money group runs ads on China biotech bill

focus

explore

WSS

How a small hospital in rural Puerto Rico survived Hurricane Maria

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

Readout Newsletter: Moderna bird flu vaccine, Biohaven, ASCO

Welsh Carson private equity firm escapes from FTC antitrust case

Childbirth

The effects of a landmark ruling on DNA ownership are becoming clearer

knowledge

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

knowledge

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

PBM executives asked to testify by House panel

23andMe had bad news about my health. I wish a person had delivered it

Akili, maker of video game for ADHD, to be acquired for 34 million

Duchenne breakthrough therapy leaves behind pioneering families

Health insurers say they are turning to AI to cut costs, improve care

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Brain MRIs reveal impact of 'toxic stress' on Black children

BioMarin wins approval for gene therapy to treat hemophilia A

Readout Newsletter: Moderna bird flu vaccine, Biohaven, ASCO

explore

Novel spinal cord stimulator treats paralysis without surgery

HHS's proposed rule does nothing to address the climate crisis

First Opinion Podcast: What happens when kids become caregivers?

Heat waves linked to early deliveries, preterm births in new study

Readout Newsletter: Insmed, Asahi Kasei, Agios, Royalty Pharma

Crowdfunding for medical bills sidesteps core problem, author says

focus

hotspot

explore

explore